Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort.

被引：0
|
作者：
Kommalapati, Ajitha
Laliotis, George
Rich, Jordan
Cumarasamy, Shivaram
Rivero, Samuel
Sharma, Shruti
Palsuledesai, Charuta C.
Malhotra, Meenakshi
Galsky, Matt D.
Elnaggar, Adam
Liu, Minetta C.
Sfakianos, John P.
Peyton, Charles
Ferguson, James
Basu, Arnab
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Natera Inc, Austin, TX USA
[3] Mt Sinai Icahn Sch Med, New York, NY USA
[4] Icahn Sch Med Mt Sinai, New York, NY USA
[5] Natera Inc, San Carlos, CA USA
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
3282-415-6705; 261-492-3532-2370-7650-2454; 283-183-138-226; 130-2818; 261-376; 5; 4; 3; 2; 38092-20390; 38092-34303; 38092-25531; 38092-18225; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.649
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：649 / 649
页数：1
相关论文
共 6 条
  • [1] Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis
    Kommalapati, Ajitha
    Laliotis, George
    Glover, Michael
    Selig, Grayce
    Kollipara, Revathi
    Mahmood, Tamara
    Shah, Sumit
    Hoimes, Christopher J.
    Stewart, Tyler F.
    Sharma, Shruti
    Malhotra, Meenakshi
    Pajak, Natalia
    Calhoun, Mark
    ElNaggar, Adam
    Liu, Minetta C.
    Basu, Arnab
    Galsky, Matt D.
    Tan, Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.
    Mehler, Shoshana
    Guilbeau, Seth
    Somer, Shmuel
    Reed, Kevin
    Greene, Heather
    Vaena, Daniel A.
    Grothey, Axel
    Somer, Brad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Personalized tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in resected non-small cell lung cancer (NSCLC) with common driver genes
    Zhong, R.
    Liang, H.
    Jiang, Y.
    Lin, Y.
    Fu, W.
    Xiong, Y.
    Xiong, S.
    Wang, R.
    Ye, Z.
    Li, X.
    Li, J.
    Li, F.
    Wang, H.
    Xiang, Y.
    Yu, Z.
    Zhan, S.
    Chen, P.
    Zheng, X.
    Liang, W.
    He, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S735 - S735
  • [4] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in stage 1-3 colorectal cancer (CRC) in clinical practice
    Somer, B.
    Mehler, S.
    Hasenburg, A.
    Greene, H.
    Tauer, K.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S347 - S347
  • [5] Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC).
    Cao, Di
    Wang, Fu-Long
    Li, Cong
    Zhang, Rong-Xin
    Wu, Xiao-Jun
    Li, Liren
    Lu, Zhen-Hai
    Pan, Zhi-Zhong
    Lin, Jun-zhong
    Wu, Miaoqing
    Liu, Yifan
    Lv, Guangzhao
    Li, Min
    Wang, Chenyang
    Li, Xi
    Chen, Gong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 213 - 213
  • [6] REAL-WORLD TISSUE-BASED CIRCULATING TUMOR DNA (CTDNA) MINIMAL RESIDUAL DISEASE (MRD) ASSAY PREDICTS OUTCOME IN LUNG CANCER PATIENTS WHO HAD CURATIVE TREATMENTS
    Oh, Youjin
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Kim, Leesul
    Yoon, Sung Mi
    Park, Joo Hee
    Djunadi, Trie Arni
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A15 - A15
1